◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral STRONG-CANDIDATE MEDIUM-HIGH

Phenylpiracetam

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict STRONG-CANDIDATE MEDIUM-HIGH

Clean stim-class racetam with measurable cognitive + physical performance benefit, well-fit to Dylan's high-cognitive-load business days and pre-MMA-training pulses. Verdict is PRN-only (not daily) because tolerance reliably builds in 1-2 weeks of daily use — this is the load-bearing limit. Confidence is MEDIUM-HIGH not HIGH because the entire human evidence base is single-source Russian (Savchenko 99-pt encephalopathy trial; ~400-pt stroke trial citation, but primary-source attribution is murky), zero independent Western RCTs exist, and the encyclopedia/secondary-source claim of "400-patient double-blind stroke trial" appears to conflate multiple smaller trials — see Open questions. What would change the verdict: independent Western RCT, better characterized tolerance kinetics in humans, or a clean Dylan A/B against pramiracetam at matched cost.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    STRONG-CANDIDATE-PRN

    Excellent fit for Dylan's high-cognitive-output business days and pre-MMA-training pulses. Tolerance speed is the *only* meaningful constraint; PRN cadence (2-3×/week) sidesteps it cleanly. Stacks well with V4 daily core (citicoline already in stack prevents headache; theanine smooths any agitation). Slots into V5 as a PRN tool alongside selank, sulbutiamine, pramiracetam — pick the right tool for the day. Plan: 200 mg AM, 2-3× per week, on heaviest cognitive-output or pre-training days. Cost ~$20-35/mo.

  • 30-50, executive maintenance
    STRONG-CANDIDATE-PRN

    Same logic; the cognitive + drive + clean stim profile fits the executive use case perfectly. Watch BP creep if hypertension is present. Don't combine with daily modafinil — alternate.

  • 50+, mild cognitive decline
    OPTIONAL-ADD-PRN

    Russian clinical use in vascular cognitive impairment is documented. Cerebrolysin and Semax/NASA likely better-supported in this age band for the cognitive-decline indication. Phenylpiracetam may add value as a PRN tool for important high-output days. Watch BP, watch interactions with cardiac meds.

  • Anxiety-prone
    OPTIONAL-ADD

    with caution. The mild anxiolytic component (benzodiazepine-receptor density upregulation) can help, but the stim profile can also worsen anxiety in some users. Pair with theanine; start at 100 mg not 200 mg. Selank is a cleaner anxiolytic pick if anxiety is the primary indication.

  • High athletic load, tested status
    SKIP

    if competing in any WADA-monitored sport. WADA-banned in-competition since 1998 (S6 stimulant); urine detection ~1.5 weeks. The Olga Pyleva 2006 Turin Olympics case (silver-medal stripped) is the cautionary tale — she took it for an injury, didn't realize the contained substance was Carphedon, lost the medal. For Dylan-archetype (untested recreational MMA): on the table. Becomes off the table if/when he transitions to amateur or pro fights subject to USADA / state athletic commission testing — cycle off and clear ~3 weeks before any tested event.

  • Sleep-disordered
    CONDITIONAL

    Insomnia risk is real if late-dosed, manageable with strict before-noon dosing. For sleep-onset insomnia (Dylan's late chronotype), AM-only dosing is fine. For sleep-maintenance insomnia, the 3-5 hour half-life means even an 11 AM dose is mostly gone by midnight, but residual sympathetic tone might persist — empirical test required.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    Cold tolerance + actoprotector profile may aid recovery from physical stress, but bromantane is better-targeted at the recovery use case. Phenylpiracetam adds the cognitive lift on top.

  • Strength/anabolic-focused
    OPTIONAL-ADD

    pre-workout. PR-improvement reports are real in untested powerlifting/strength contexts. 100-200 mg ~30-60 min pre-session is the standard pre-workout protocol. Not anabolic itself; works on the neural-drive side.

▸ Subjective experience (deep)

Onset: 30-60 minutes, often noticed within the first hour even on first dose (unlike bromantane which builds over a week).

Peak: 1-3 hours post-dose. Plasma Tmax ~1 hour; subjective peak slightly delayed.

Duration: 4-6 hours of clear effect, with a soft taper. The 3-5 hour half-life means most of the lift is gone by 8-10 hours post-dose, with no significant rebound.

Characteristic phenomenology (compiled from Russian clinical descriptors + Western anecdote):

  • Clean stim lift — clearer drive, faster mental tempo, improved task initiation. Notably not jittery the way caffeine + amphetamine can be. The closest Western analog is a clean modafinil dose at ~150 mg.
  • Mood lift — mild, not euphoric; described as "motivated" rather than "happy." DAT inhibition tracks here.
  • Physical performance edge — measurable in athletes: reduced perception of effort, improved endurance, faster reaction time. The "WADA-banned for a reason" effect.
  • Cold tolerance — the genuinely distinctive effect. Users report being noticeably less affected by cold environments (cold rooms, winter outdoors, ice baths). Cosmonaut-origin signal showing through.
  • Improved verbal fluency + decision-making — characteristic racetam-class effect, more pronounced than piracetam due to stim component.
  • Sleep usually preserved if dosed before noon — late dosing reliably costs sleep onset (universal report).
  • First-dose effect is real — unlike bromantane, you feel the first dose. This is part of why phenylpiracetam is so popular in biohacker circles and so suspect for tolerance.
  • Tolerance is real and fast — most users report diminishing returns after 5-10 days of daily use; some within 2-3 days. After ~2 weeks daily, the lift is largely gone. This is the load-bearing limitation.

Compared to modafinil: similar wakefulness/drive component, shorter duration, more physical-performance lift, more cold tolerance, faster tolerance. Modafinil is daily-safe; phenylpiracetam is not. Compared to pramiracetam: phenylpiracetam has the stim lift; pramiracetam has the deeper memory/learning effect. Different tools — pramiracetam for sustained daily cognitive work, phenylpiracetam for high-output spike days. Compared to bromantane: phenylpiracetam is acute and tolerance-prone; bromantane is gradual and tolerance-resistant. Different time horizons. Compared to sulbutiamine: similar PRN-only / tolerance-fast profile; phenylpiracetam is stronger and more cognitive, sulbutiamine is more mood/energy. Both 2-3×/week max. Compared to L-tyrosine: tyrosine is substrate-only and only works under acute stress depletion; phenylpiracetam is enzyme-active and works regardless of stress state. Different mechanisms; can stack.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: FAST. This is the load-bearing constraint. Daily 100-200 mg use → noticeable tolerance within 5-14 days for most users; some within 2-3 days. After ~2 weeks daily, effect largely gone. The mechanism is presumably DAT-receptor downregulation + counter-adaptive DA receptor changes, similar in pattern to amphetamine tolerance but at the synaptic-protein level rather than the dopamine-pool-depletion level.
  • Recommended cycle: PRN only, 100-200 mg, 2-3× per week maximum, with at least 1-2 days off between doses. Total weekly load: 200-600 mg (i.e., 2-3 doses of 100-200 mg). This is the empirical sweet spot from biohacker community + Russian intermittent-dosing protocols.
  • Reset protocol if needed: 2-week complete break to baseline; some users need 3-4 weeks. During reset, swap to a different mechanism (pramiracetam, modafinil, bromantane) to maintain stack effect.
  • Long-term cycling pattern (months/years): Run 4-8 weeks of 2-3×/week PRN, then 1-2 week complete break. Repeat indefinitely. No documented long-term safety concerns at this cadence over the ~20 years of Russian clinical use.
  • No documented kindling effect — tolerance resets cleanly after washout, doesn't get progressively faster with repeated cycles.
▸ Stacking deep dive

Synergistic with

  • alpha-gpc / citicoline (Dylan's V4 includes 500 mg citicoline daily): Mandatory pairing to prevent racetam headache and amplify cognitive effect. Pre-dose by 30-60 min.
  • l-tyrosine: Theoretical synergy via increased DA substrate when reuptake is blocked. Anecdotal reports mixed but mostly positive. Try 500-1000 mg with phenylpiracetam dose.
  • pramiracetam: Different mechanism (HACU enhancement vs. DAT inhibition), no cross-tolerance reported. Can be used on alternate days — pramiracetam for sustained daily cognitive work, phenylpiracetam for spike days.
  • sulbutiamine: Similar PRN profile, complementary mechanism (thiamine derivative, mild DA via different pathway). Can stack on the same PRN day for combined drive + cognitive effect, but watch for tolerance kindling — alternate which compound leads each PRN day.
  • modafinil: Different DAT-binding kinetics; functionally synergistic for wakefulness + drive, but don't stack same-day on a routine basis — phenylpiracetam should be a break from daily modafinil rather than an addition. On a heavy-output day, low modafinil (50-100 mg) + phenylpiracetam (100 mg) is a known stack but use sparingly.
  • L-theanine (Dylan's V4 has 200 mg): Smoothing partner — softens any mild irritability/agitation, no efficacy compromise.
  • Magnesium (Dylan's V4): Neutral-positive; helps sleep onset on phenylpiracetam days if dosed PM.
  • Creatine (Dylan already takes): Synergistic for the physical-performance arm; both improve high-output cognitive + physical work.
  • Beta-alanine (Dylan's V4): Synergistic for endurance / training-day applications.

Avoid stacking with

  • Other DAT inhibitors same-day (modafinil daily-stack, amphetamine, methylphenidate, bromantane): additive sympathetic + DA tone, hypertension/anxiety/sleep risk. Pick one per day.
  • High-dose caffeine (>200 mg): additive stimulation, jitter risk. Low caffeine (50-100 mg) is fine.
  • Phenibut: not a pharmacological interaction concern, but the GABA-B agonism + stim lift produces a "rollercoaster" subjective profile most users dislike. Skip.
  • MAOIs (non-selective): theoretical hypertensive risk. Not relevant for Dylan.
  • Other racetams same-day: mostly redundant (cholinergic load + cognitive overlap). Pick one racetam per day.

Neutral / safe co-administration

Dylan's V4 daily core is fully compatible: DHA, magnesium glycinate, magnesium L-threonate, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, L-theanine, glycine, D3+K2, beta-alanine, vitamin C. Cerebrolysin pairing reported neutral-to-positive (different MoA, different cycle structure). Selegiline at 1-2.5 mg (MAO-B selective) is probably fine but watch HR/BP first 2 weeks.

▸ Drug interactions deep dive
  • CYP enzymes: Phenylpiracetam is not metabolized — excreted ~100% unchanged. No CYP induction or inhibition expected. This is unusual and clinically convenient — no concerns about contraceptive efficacy, statin exposure, SSRI levels, etc.
  • Hormonal contraceptives: No expected interaction.
  • Antidepressants:
    • SSRIs / SNRIs: no documented interaction; theoretical caution given DAT inhibition adds to NE-side load on top of an SNRI like venlafaxine — monitor BP if combining.
    • MAOIs (non-selective): theoretical hypertensive risk via DA reuptake inhibition meeting MAO inhibition.
    • Bupropion (also a DAT/NET inhibitor): additive — avoid stacking on a daily basis. Dylan's V5 plan considers bupropion as a contingency add — if bupropion goes in, phenylpiracetam comes out of routine PRN.
  • Stimulants: see Avoid stacking section.
  • Anticonvulsants: Russian literature documents adjunct use for epilepsy at lower doses, but theoretical seizure threshold concerns exist. Not relevant for Dylan.
  • Anticoagulants / antiplatelets: No documented interaction. Phenylpiracetam may marginally improve erythrocyte deformability and capillary flow (piracetam-class effect) but this is not at clinically significant magnitude.
  • Alcohol: No documented interaction; Russian protocols don't restrict. Not relevant for Dylan (zero alcohol baseline).
▸ Pharmacogenomics
  • COMT Val158Met: COMT-Met/Met carriers (slow DA degradation) may experience stronger response — phenylpiracetam blocks reuptake, COMT-Met/Met means less clearance after reuptake. Theoretically the "supercharged response" genotype. Not directly tested with phenylpiracetam but mechanistically expected. Worth checking against Dylan's 23andMe results (~June 2026).
  • DAT1 (SLC6A3) VNTR polymorphism: 9R carriers (lower DAT density) might experience different baseline DA tone, with theoretically smaller marginal lift from DAT inhibition. 10R/10R carriers (higher DAT density) might respond more strongly. Not clinically tested.
  • DRD2 polymorphisms: A1 allele (lower receptor density) carriers might respond differently to the indirect D2 upregulation seen in Russian preclinical data. Not characterized in humans.
  • CYP polymorphisms: Irrelevant — phenylpiracetam is not CYP-metabolized.
  • Sex differences: Not characterized in published literature. Bromantane has documented sex-divergent PK; phenylpiracetam has not been similarly studied.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market (pharma-grade Russian) RUPharma — Phenotropil® / Nanotropil Novo® / Aktitropil® 100 mg × 30 tabs $25-40 / 30 tabs ($0.85-1.30/dose) High — Pharmstandard-manufactured pharma-grade tablets, third-party batch verification, ~200 5★ Trustpilot reviews Top pick. RUPharma resumed shipping to US Dec 2025. Multiple brands (all same drug, same Pharmstandard manufacturer): Phenotropil® (original brand reissued post-2020 licensing fix), Nanotropil Novo® (newer brand, identical formulation), Aktitropil® (newer brand, identical formulation, often best in stock). At 100-200 mg per dose × 2-3×/week = 30 tabs covers ~2-3 weeks. ~$20-35/mo PRN cost.
Gray-market (Russian) CosmicNootropic — Phenotropil / Nanotropil Novo 100 mg × 30 tabs ~$30-45 / 30 tabs High — operating since 2016, decent reputation, same Pharmstandard sourcing Solid backup if RUPharma stocks out. Slightly higher prices, similar shipping.
Research-chem (powder) Nootropics Depot (US) not currently stocked (phenylpiracetam delisted ~2019 due to FDA pressure) N/A NSI no longer stocks; powder form generally available only via international research-chem vendors.
Research-chem (powder) Various international research-chem vendors $20-35 / 5g ($0.40-0.70 per 100 mg dose) Medium — quality variable, CoA mandatory Cheaper but requires accurate scale (100 mg = 0.1 g), and you lose the pharma-grade tablet QA. Pharma tabs are worth the small premium.
Avoid Random eBay / Amazon listings Variable Low Phenylpiracetam on mainstream platforms is often counterfeit or contaminated.

Sourcing reality 2026:

  • Pharma-grade tabs are available again — Pharmstandard reissued the drug ~2020 after the 2017-2018 registration gap. Three brand names (Phenotropil, Nanotropil Novo, Aktitropil) are all the same compound from the same manufacturer; pick whichever is in stock at RUPharma.
  • Cost: ~$20-35/month for Dylan's PRN cadence (2-3 doses/week of 100-200 mg). Pharma tabs are cheap relative to the cognitive output they enable.
  • No CoA / scale gambling needed — buy the tabs, not the powder. This is one of the few Russian compounds where the pharma-grade product is reliably available.
  • Recommendation for Dylan: RUPharma Aktitropil® or Nanotropil Novo® 100 mg × 30 tabs as primary; CosmicNootropic as backup. One 30-tab pack ≈ 2-3 weeks at PRN cadence; order 2-3 packs at a time for 1-2 month supply.
▸ Biomarkers to track (deep)
  • Baseline (before starting): Resting HR, BP, sleep onset latency (subjective or wearable), subjective cognitive output rating (1-10 daily for 1 week pre-pulse). For Dylan: also Ring-Health HRV trend baseline (Colmi R06 deployment), training-day RPE / readiness scores.
  • During use (each PRN day): Same-day cognitive output rating, sleep onset that night (most sensitive metric), HR/BP if any concerns, subjective phenomenology log (drive level, jitter level, mood, cold tolerance if relevant). After 4-6 weeks of PRN use: pattern-match across days — did it consistently lift output, or only randomly?
  • Tolerance check: Compare "best PRN day in week 1" vs. "best PRN day in week 8" subjective rating at matched dose. If trending down, take a 2-week break.
  • Post-cycle (if cycled): No specific labs needed (no hepatic/CYP load). Subjective baseline-return check 1-2 weeks post-stop.
  • Annual: Standard Dylan bloodwork (June + ongoing) — no phenylpiracetam-specific labs required, but BP trend is worth watching.
▸ Controversies / open debates Live debate

1. The "400-patient double-blind RCT" claim — likely conflation. The encyclopedia and many secondary sources cite a 400-patient double-blind RCT in stroke patients showing benefit. Primary-source verification is murky — the Savchenko 2005 paper (PMID 16447562) is 99 patients, open-label, not 400, not double-blind. There are multiple smaller Russian stroke trials in the 2003-2010 window that, when pooled, total roughly 400 patients across ischemic stroke recovery indications. The "400-patient" figure appears to be aggregate or summary, not a single RCT. Encyclopedia accuracy flag. This does not invalidate the post-stroke evidence (the pooled signal is real and consistent), but the rigor of the citation is weaker than usually claimed.

2. WADA ban year — 1998, not 2002. WADA's prohibited list shows phenylpiracetam (carphedon/fonturacetam) banned in-competition since 1998, when WADA was newly formed. The "2002" figure in some user-summaries may stem from confusion with the high-profile 2006 Turin Olympics Olga Pyleva case (often misremembered as 2002 Salt Lake City) or from pre-WADA IOC banning prior to formal WADA codification. Encyclopedia/task-prompt accuracy flag. The S6 stimulant classification is current as of 2026 and detection capability is well-established.

3. The Olga Pyleva 2006 Turin case — context matters. Pyleva (now Medvedtseva) was the first athlete disqualified at Turin 2006, stripped of her women's 15 km biathlon silver medal. She tested positive for carphedon/phenylpiracetam from a prescription medication taken for an ankle injury — Phenotropil (the Russian pharma brand) did not list carphedon explicitly on the packaging, and the Russian Olympic Committee had reportedly asked the manufacturer to label it more clearly. The case is sometimes framed as "athlete cheating with phenylpiracetam"; the documented reality is closer to "athlete used a prescribed medication unaware of its WADA status." Dylan's profile (untested recreational MMA) is unaffected, but the case illustrates how easy WADA violations are with this compound.

4. Tolerance kinetics — single number doesn't fit. Reports range from "tolerance in 2-3 days" to "tolerance after 45-60 days at 100 mg/day." Most plausible explanation: dose-dependent and individual-variation. Lower doses (100 mg) build tolerance more slowly than higher doses (200 mg). High-DAT-density genotypes may tolerate longer; low-DAT-density genotypes hit ceiling faster. The conservative recommendation (PRN-only, 2-3×/week) sidesteps the variance.

5. R vs. S enantiomer — the racemate vs. pure-R question. Pharma-grade Phenotropil/Nanotropil/Aktitropil is the racemate (50:50 R/S). Most of the activity comes from R-phenylpiracetam — S is roughly inactive on locomotor stimulation and DAT inhibition (though S has its own selective DAT inhibition profile examined for body weight reduction in Zvejniece 2017). Pure R-phenylpiracetam (MRZ-9547, Merz development name) is theoretically more potent at half the dose, but is not commercially available — Merz's Parkinson's-fatigue program stalled and pure-R is research-chem only. Practical implication: stick with the racemate (pharma-grade tabs); pure-R via research-chem is more expensive and not meaningfully better at therapeutic doses.

6. The "AChE-like effect" framing. The encyclopedia / task-prompt phrasing of "AChE-like effects" is loose — phenylpiracetam is not an acetylcholinesterase inhibitor. The cholinergic effect is via direct α4β2 nAChR modulation (IC50 ~5.86 μM) and downstream ACh-utilization, which produces functionally similar "more cholinergic tone" phenomenology but via a different mechanism than huperzine A or donepezil. The choline-supplement requirement (alpha-GPC / CDP-choline pre-dose) reflects the increased ACh utilization, not AChE inhibition. Mechanism precision flag.

7. Mechanism precision overall — older Russian framing vs. newer molecular work. Russian primary literature (1983-2010) framed phenylpiracetam as a "neurotransmitter density modulator" without molecular-level binding data — lots of Bmax measurements, less IC50 data. Newer Western work (Zvejniece 2011, 2017; Tanda 2009; Merz MRZ-9547 program) pinned down the DAT/NET binding constants and effort-based behavioral profile. The encyclopedia's "DA reuptake inhibition + AChE-like + adaptogenic" framing is a reasonable lay summary but conflates mechanisms — it's DAT/NET inhibition (not "DA reuptake" generally), nAChR modulation (not AChE inhibition), and the "adaptogenic" framing is class-level cosmonaut-context language without a single molecular substrate.

8. The Merz / MRZ-9547 program failure as negative signal. A major Western pharma (Merz) developed pure R-phenylpiracetam for Parkinson's-related fatigue and the program did not advance. This is meaningful: Merz had the regulatory capacity, the capital, and the disease target — they didn't proceed. Possible explanations: insufficient effect size in target population, tolerance problem too pronounced for chronic dosing, or strategic deprioritization. The cleanest reading: for chronic-fatigue indications requiring daily dosing, the tolerance kinetics are a fundamental obstacle. For PRN cognitive-spike use, this is irrelevant — the tolerance problem dissolves with 2-3×/week cadence. Verdict-confidence MEDIUM-HIGH (not HIGH) reflects this.

9. WADA detection vs Dylan's status. WADA-banned in-competition (S6 stimulant) and detectable for ~1.5 weeks in urine. Dylan trains MMA recreationally, untested in any sanctioned competition — WADA status is irrelevant. Becomes relevant only if he transitions to amateur or pro fights subject to USADA / state athletic commission testing. Cycle off and clear 3+ weeks before any tested event.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: STRONG-CANDIDATE-PRN, MEDIUM-HIGH confidence. Mechanism is well-characterized at the molecular level (DAT inhibition + α4β2 nAChR + indirect receptor density upregulation), Russian clinical signal across ~30 years of cosmonaut/athlete/clinical use is strong, subjective effects (clean stim lift + drive + cognitive throughput + cold tolerance) fit Dylan's high-cognitive-output PRN profile excellently. The tolerance constraint forces PRN-only cadence (2-3×/week max), which Dylan can comfortably accommodate. Confidence is MEDIUM-HIGH (not HIGH) because (a) the entire human evidence base is Russian / single-source, (b) zero independent Western RCTs, (c) the "400-pt double-blind" claim is unverifiable as a single trial, (d) Merz's MRZ-9547 program for chronic-use indication failed to advance, suggesting the tolerance problem is real and pharma-relevant. Plan: PRN tool in V5, 200 mg AM with 500 mg citicoline pre-dose, 2× per week on heaviest cognitive output or pre-training days. RUPharma Aktitropil® / Nanotropil Novo® 100 mg × 30 tabs, ~$25-40/pack, ~$20-35/month. Would upgrade to STRONG-CANDIDATE-HIGH if (a) independent Western RCT replicates Russian signal, OR (b) Dylan runs 4-6 weeks of clean PRN with measurable cognitive output gains over baseline.
▸ Open questions / gaps Open
  1. Is there a single 400-patient double-blind RCT, or is it an aggregate? Primary-source verification needed. Suspect the "400-pt" figure is pooled across multiple smaller Russian trials.
  2. What is the actual tolerance kinetics curve at 100 mg vs. 200 mg PRN cadence? Empirical n=1 needed — Dylan should track subjective output ratings across 4-6 weeks of 2×/week 200 mg use to characterize his personal tolerance profile.
  3. Does COMT-Met/Met genotype predict stronger response? Theoretically yes (lower DA clearance + DAT inhibition = bigger marginal effect). Worth checking against Dylan's 23andMe results (~June 2026).
  4. Why did Merz's MRZ-9547 (R-phenylpiracetam) Parkinson's-fatigue program stall? Public disclosures are limited. Likely tolerance kinetics + insufficient chronic-dose effect size, but uncertain.
  5. Cold-tolerance human data? Anecdotal and rodent only. No formal human cold-stress trial. Plausible but uncharacterized.
  6. Does PRN (2-3×/week) cadence sustain effect indefinitely, or is there long-term cycling decay? No published data past ~8 weeks. Russian clinical use is generally 30-90 day courses, not chronic intermittent.
  7. Dylan-specific A/B vs. pramiracetam at matched cost? Useful comparison — different mechanisms, different cognitive flavors. Worth running each for 4 weeks PRN to characterize.
  8. What is the actual purity / potency of pharma-grade Russian product in 2026? Pharmstandard tabs should be reliable, but Russian-pharma supply chain has had QA issues historically. Single-batch HPLC verification on a starter pack would be the cautious approach.
▸ Sources (full, with our context)
Back to compact view